---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-060693"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-05-14T11:20:27+00:00"
generated_at: "2026-05-14T11:26:28.518387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing

## Summary
- Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.
- Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.
- Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.
- Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.
- Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy.

## SEC filing metadata
- accession: 0001104659-26-060693
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-05-14T11:20:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/0001104659-26-060693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-060693
- JSON: https://secwatch.observer/filing/0001104659-26-060693.json
- Plain text: https://secwatch.observer/filing/0001104659-26-060693.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/0001104659-26-060693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.